3-(4-methoxynaphthalen-1-yl)acrylic acid | 15971-30-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3-(4-methoxynaphthalen-1-yl)acrylic acid
• 英文别名: 3-(4-methoxy-naphthalen-1-yl)-acrylic acid；3-(4-methoxy-[1]naphthyl)-acrylic acid；3-(4-Methoxy-[1]naphthyl)-acrylsaeure；β-(4-Methoxy-naphthyl-(1))-acrylsaeure；3-(4-Methoxynaphthyl)acrylic acid；3-(4-methoxynaphthalen-1-yl)prop-2-enoic acid
• CAS: 15971-30-9
• 化学式: C₁₄H₁₂O₃
• mdl: MFCD00156955
• 分子量: 228.247
• InChiKey: BDWSMCXLZKKQFV-UHFFFAOYSA-N

物化性质

• 熔点：
  225°C
• 沸点：
  185-200 °C(Press: 40 Torr)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  3-(4-methoxynaphthalen-1-yl)acrylic acid 在 氢气 、 sodium carbonate 、 钯 作用下， 生成 4-甲氧基-1-萘丙酸
  参考文献：
  名称：

  Windaus; Bernthsen-Buchner, Chemische Berichte, 1917, vol. 50, p. 1122

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(羟甲基)-4-甲氧基萘 在 水 、 sodium hydride 、 pyridinium chlorochromate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 生成 3-(4-methoxynaphthalen-1-yl)acrylic acid
  参考文献：
  名称：

  Evaluation of synthetic naphthalene derivatives as novel chemical chaperones that mimic 4-phenylbutyric acid

  摘要：

  The chemical chaperone 4-phenylbutyric acid (4-PBA) has potential as an agent for the treatment of neurodegenerative diseases. However, the requirement of high concentrations warrants chemical optimization for clinical use. In this study, novel naphthalene derivatives with a greater chemical chaperone activity than 4-PBA were synthesized with analogy to the benzene ring. All novel compounds showed chemical chaperone activity, and 2 and 5 possessed high activity. In subsequent experiments, the protective effects of the compounds were examined in Parkinson's disease model cells, and low toxicity of 9 and 11 was related to amphiphilic substitution with naphthalene. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.080

文献信息

• Traceless directing group mediated branched selective alkenylation of unbiased arenes
  作者：Soumitra Agasti、Aniruddha Dey、Debabrata Maiti

  DOI：10.1039/c6cc07032a

  日期：——

  –COOH group assisted branched selective olefination of simple arenes.

  –COOH基团辅助简单芳烃的分支选择性烯基化。

• Benzophenalenofurans
  申请人：SmithKline Corporation

  公开号：US03985896A1

  公开（公告）日：1976-10-12

  The compounds are benzophenalenofurans having pharmacological activity, in particular, coronary vasodilator activity.

  这些化合物是苯并菲啶呋喃类，具有药理活性，特别是冠状动脉血管扩张活性。
• Therapeutic agent for Parkinson's disease
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US05484920A1

  公开（公告）日：1996-01-16

  Agents for the treatment of Parkinson's disease contain, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## in which R.sup.1, R.sup.2 are R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 represents cycloalkyl, --(CH.sub.2).sub.n --R.sup.5 (in which R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or ##STR2## in which Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, ##STR3## in which R.sup.6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 represent independently O or S.

  帕金森病的治疗剂含有黄嘌呤衍生物或其药学上可接受的盐作为活性成分。黄嘌呤衍生物由以下式子表示：##STR1## 其中R.sup.1、R.sup.2和R.sup.3分别表示氢、低碳基、低烯基或低炔基；而R.sup.4表示环烷基、--(CH.sub.2).sub.n --R.sup.5（其中R.sup.5表示取代或未取代的芳基或取代或未取代的杂环基；n为0到4的整数），或##STR2## 其中Y.sup.1和Y.sup.2分别表示氢、卤素或低碳基；而Z表示取代或未取代的芳基，##STR3## 其中R.sup.6表示氢、羟基、低碳基、低烷氧基、卤素、硝基或氨基；m表示1到4的整数，或取代或未取代的杂环基；而X.sup.1和X.sup.2分别表示氧或硫。
• Antidepressants
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US05543415A1

  公开（公告）日：1996-08-06

  The present invention relates to an antidepressant containing as an active ingredient a xanthine derivative or a pharmaceutically acceptable salt thereof, the xanthine derivative being represented by Formula (I) : ##STR1## in which R.sup.1, R.sup.2, and R.sup.3 represent independently hydrogen, lower alkyl, lower alkenyl; R.sup.4 represents cycloalkyl, --(CH.sub.2).sub.n --R.sup.5 (in which R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or ##STR2## (in which Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen or lower alkyl; and Z represents substituted or unsubstituted aryl, ##STR3## (in which R.sup.6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 3), or a substituted or unsubstituted heterocyclic group); and X.sup.1 and X.sup.2 represent independently O or S.

  本发明涉及一种抗抑郁剂，其活性成分为黄嘌呤衍生物或其药学上可接受的盐，该黄嘌呤衍生物由式(I)表示： ##STR1## 其中R.sup.1，R.sup.2和R.sup.3分别独立表示氢，低烷基，低烯基；R.sup.4表示环烷基，--(CH.sub.2).sub.n --R.sup.5（其中R.sup.5表示取代或未取代的芳基或取代或未取代的杂环基；n为0至4的整数），或##STR2##（其中Y.sup.1和Y.sup.2分别独立表示氢，卤素或低烷基；Z表示取代或未取代的芳基，##STR3##（其中R.sup.6表示氢，羟基，低烷基，低烷氧基，卤素，硝基或氨基；m表示1至3的整数），或取代或未取代的杂环基）；X.sup.1和X.sup.2分别独立表示O或S。
• Rousset, Bulletin de la Societe Chimique de France, 1897, vol. <3> 17, p. 814
  作者：Rousset

  DOI：——

  日期：——